The 2024–2025 flu season was notably intense and more prolonged compared to previous years.
Regarding SARS-CoV-2, the season was characterised initially by two waves in the summer and autumn of 2024 and ended with a period of lower intensity.
Compared with the previous season, the 0–5-month age group was significantly less affected by the RSV epidemic. This observation is consistent with the launch of the first immunization campaign (Nirsevimab) for young children in Belgium.
2.Syndromic surveillance
During the 2020-2021 and 2021-2022 seasons, health measures were put in place to stop the spread of the SARS-CoV-2 virus. These measures also reduced other respiratory infections. From spring 2022, more respiratory viruses other than SARS-CoV-2 began to circulate again in the population.
The 2024-2025 season extended from week 25 of 2024 (17 June) to week 24 of 2025 (15 June).
During the 2024–2025 season, the number of new ILI cases reached its highest level recorded in 10 years
During the 2024–2025 season, general practitioner (GP) consultations for influenza-like illness (ILI) peaked at 1,233 per 100,000 in the last week of January 2025, far above the previous season’s 638 per 100,000. Consultations for other acute respiratory infections (ARI) also peaked in the same week, although remaining below the low-activity threshold. This coincided with the flu epidemic. The second COVID-19 wave (mid-September to mid-October 2024) slightly affected ILI consultations but stayed below the low-activity threshold.
During the 2024–2025 season, the number of new ILI consultations was highest in young children
During the 2024–2025 season, the number of new consultations for influenza-like illness (ILI) was highest among 0–14-year-olds, and lowest among individuals aged 65 years and older, which nevertheless represents a larger proportion of the Belgian population than children. Within the 0–14 age group, the number of consultations for acute respiratory infections (ARI), other than ILI, was higher in children aged 0 to 4 years than in those aged 5 to 14 years, but this was not observed for consultations for ILI.
SARI hospitalizations in the 2024-2025 season followed a similar pattern to last season
Hospitalizations for severe acute respiratory infections (SARI) followed a pattern similar to the previous season. Three peaks were observed: one in mid-December 2024 during the RSV epidemic, a second in late January 2025 at the height of the flu epidemic, and a third in mid-February 2025.
Children aged 0–4 had the highest hospitalization rates, while older adults experienced more severe outcomes
Children aged 0–4 had the highest hospitalization rates, with a peak in mid-December, coinciding with the RSV epidemic. Older adults had lower rates but more severe outcomes. Winter 2024–2025 saw an excess mortality (+1.9%), especially among those 85+, coinciding with flu and RSV epidemics, smog, and a cold wave [3].
Weekly number of new cases for 100,000 inhabitants of patients hospitalized for SARI, by age group, Belgium, 2024-2025 season Source: Sciensano, network of sentinel hospitals [2]
3.Flu
The flu season reached its peak in late January 2025
The flu epidemic began in mid-December 2024 (week 50) and lasted until early March 2025 (week 10). It reached a peak of 692 confirmed cases per 100,000 inhabitants in late January 2025 (week 4). Around 540,000 people were affected by influenza-like illness (ILI) caused by flu during the 2024–2025 season in Belgium, representing about 5% of the total population.
For this season, the effectiveness of seasonal flu vaccines in Belgium was estimated at 44% for preventing GP consultations and 17% for preventing hospitalizations.
The 2024–2025 flu season in Belgium was long and particularly intense
The epidemic lasted an unusually long 13 weeks and was exceptionally intense, with more than 4,500 cases per 100,000 inhabitants reported over the entire season—higher than any total recorded in the previous 10 years.
Hospitalizations for flu-confirmed SARI peaked in mid-January 2025, with 15% experiencing severe complications
During the 2024–2025 season, the peak of hospital admissions for flu-confirmed SARI occurred in mid-January (weeks 3 and 4). The maximum new cases during this season were slightly higher than in the previous season. However, due to changes introduced in the SARI surveillance system in 2023, including increased coverage, improved data quality, and shorter reporting delays, comparisons between seasons should be interpreted with caution.
During this winter season, 15% of patients hospitalized with flu-confirmed SARI experienced severe complications. Among those patients, 4% died.
Weekly number of new cases for 100,000 inhabitants of patients hospitalized for SARI, positive for flu, Belgium, 2024–2025 season Source: Sciensano, sentinel hospital network [2]
4.COVID-19
No COVID-19 wave was observed during the winter of 2024-2025
The year 2024 was marked by two waves of SARS-CoV-2 during the summer (mid-June - beginning of August 2024) and in autumn (mid-September – mid-October 2024), with moderate intensity compared to the waves observed in the previous year (December 2023). The first part of 2025 saw a new, smaller SARS-CoV-2 wave. During this season 2024-2025 , three COVID-19 waves were thus observed. From the end of October 2024 till the end of the season, about 25,000 COVID-19 cases were confirmed in Belgium.
Weekly number of new cases for 100,000 inhabitants of suspected and confirmed COVID-19 infections, Belgium, 2024-2025 season Source: COVID-19 barometer of general practitioners [4] Data on general practitioner consultations for suspected or confirmed COVID-19 come from the new GP infection barometer, which started in October 2024; as a result, data are not available from the very beginning of the season.
Hospitalizations for SARS-CoV-2–confirmed SARI were lower during the 2024–2025 season compared to previous seasons
The highest number of new hospitalizations with confirmed COVID-19 recorded by the SARI network was observed during the first wave of the season, with 3.1 hospitalizations per 100,000 inhabitants for SARS-CoV-2 in mid-September 2024, a value lower than those observed at the peaks of waves during the two previous seasons.
Caution is advised when interpreting age-specific trends in SARICOVID-19 infections, as the weekly number of positive samples is low. Nevertheless, it is observed that the age groups with the highest number of new cases among hospitalized SARI patients with confirmed SARS-CoV-2 infection are 0–4 years and 65 years and older.
Among SARI patients who tested positive for SARS-CoV-2, 12% experienced severe complications during the first wave (mid-June to end of July) of the season, and 16% experienced severe complications during the second wave (mid-September to mid-October).
The available data show that in Belgium, COVID-19 vaccination prevented 52% of hospitalizations among adults aged over 65 years during the 2024–2025 winter season.
Weekly number of patients hospitalized for SARI for 100,000 inhabitants, positive for SARS-CoV-2, Belgium, 2024-2025 season Source: Sciensano, sentinel hospital network [2]
5.Respiratory Syncytial Virus
The 2024–2025 RSV epidemic followed a typical seasonal pattern in Belgium
The RSV epidemic lasted 12 weeks, extending from week 46 (mid-November 2024) to week 05 (early February 2025). The peak of the epidemic was reached in week 50 (December 2024), with 969 positive tests reported. However, these positive samples were reported by participating sentinel laboratories and do not represent the national total.
The profile of this epidemic (in terms of intensity and duration) is consistent with what is typically observed in Belgium.
Weekly number of RSV-positive samples, Belgium, 2024-2025 season Source: Sciensano, network of sentinel laboratory [5] The positive samples are reported by participating sentinel laboratories and do not represent the national total.
Most positive samples are detected in children aged 0–4 years
By age group, the majority of RSV-positive samples were detected in the youngest group—children aged 0 to 4 years—during the 2024-2025 season. Young children were the most affected by RSV infection and therefore the most frequently tested for this pathogen.
There is a clear difference in the timing of the epidemic between young children and adults. While young children experienced an earlier peak at the end of November, the older age group reached their peak later, at the beginning of January.
Weekly number of RSV-positive samples, by age group, Belgium, 2024-2025 season Source: Sciensano, network of sentinel laboratory [5] The positive samples are reported by participating sentinel laboratories and do not represent the national total. Age-specific data should be interpreted with caution due to potential bias from the testing strategy.
The 2024–2025 RSV season saw a high peak in confirmed SARI hospital admissions
The number of new hospitalized patients (SARI) positive for RSV peaked at 6.6 hospitalizations per 100,000 inhabitants in late November to early December, representing a higher intensity than in the previous two seasons. However, differences between seasons should be interpreted with caution due to the significant changes implemented in SARI surveillance in November 2023. This peak was almost entirely driven by the 0–4 years age group.
Among SARI patients positive for RSV, 9.3% experienced severe complications during the epidemic (mid-November – end of January). In the 0–4 years age group, 6.4% of hospitalized children with SARI positive for RSV experienced severe complications during the epidemic.
Weekly number of new patients hospitalized for SARI per 100,000 inhabitants, positive for RSV, Belgium, 2024-2025 season Source: Sciensano, sentinel hospital network [2]
The RSV immunisation effectively reduced hospitalizations among the youngest children
Focusing specifically on RSV hospitalizations among young children, the burden was highest in those under 1 year of age. Compared to the previous season, the 0–5-month age group was notably less affected by the epidemic. This observation aligns with the launch of the first immunization campaign (Nirsevimab) for young children in Belgium. The effectiveness of RSV immunization against hospitalization among children under 4 years of age was estimated at 86% for the 2024–2025 season.
Weekly number of new hospitalized SARI patients with confirmed RSV per 100,000 inhabitants in each age group (0–4 years), Belgium, 2024–2025 season Source: RSVPed [6]
Since spring 2022, an increasing number of respiratory viruses other than SARS-CoV-2 have resumed circulation in the population. During the 2024–2025 season, the incidence of acute respiratory infections followed a seasonal trend—rising in the fall, remaining high throughout the winter, and declining in the spring—marked by the overlapping circulation of various respiratory pathogens, including flu, SARS-CoV-2, and RSV.
Influenza-like illness (ILI) refers to a group of symptoms that suggest a viral respiratory infection, including fever, chills, dry cough, fatigue, and muscle aches. These symptoms can be caused by various viruses, such as flu, RSV, adenovirus, parainfluenza, or SARS-CoV-2. Seasonal flu is caused by Influenza viruses type A and B, which circulate each winter and are known for frequent mutations. This variability requires the flu vaccine to be updated regularly. Most people recover within a couple of weeks, but serious complications may occur in high-risk groups, including the elderly, people with chronic diseases, pregnant women, and very young children [7].
SARS-CoV-2, the virus responsible for COVID-19, emerged in late 2019 and caused a global pandemic. It spreads mainly through respiratory droplets and aerosols. The severity of illness varies depending on the variant and individual immunity. During the 2020–2021 and, to a lesser extent, the 2021–2022 seasons, public health measures (e.g. mask use, distancing) helped reduce not only COVID-19 transmission but also the spread of other respiratory viruses. In May 2023, the WHO declared the end of COVID-19 as a public health emergency of international concern, leading to changes in testing strategies [7].
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in young children but can also affect adults—especially older adults or those with weakened immune systems. RSV is highly contagious and spreads via droplets. In Belgium, RSV typically circulates from October to March, with peaks in December or January. Since 2024 immunization of infants with monoclonal antibodies and maternal vaccination has been available in Belgium. Since 2025, vaccination has also been offered to the elderly and adults with comorbidities [7].
In Belgium, the surveillance of acute respiratory infections is coordinated by Sciensano. It relies on several sentinel networks, including general practitioners, laboratories and hospitals. These networks report weekly on the number of ILI and SARI cases. Differences between seasons should be interpreted with caution for SARI, given significant changes made to SARI surveillance in November 2023, which improved paediatric RSV surveillance. Surveillance of ILI is also carried out by a sentinel network of nursing homes, which assesses the number of ILI cases, hospitalizations and ILI-related deaths. Virological surveillance helps assess the circulation of seasonal flu, SARS-CoV-2, and RSV. In addition, flu, SARS-CoV-2, and RSV are also monitored through wastewater surveillance [7].
The Be-MOMO surveillance system is used to quantify excess mortality that may result from epidemics such as flu, COVID-19, and RSV.
Definitions
Acute Respiratory Infection (ARI)
Sudden/acute onset of respiratory symptoms, with or without fever or malaise, including a wide range of episodes such as colds, rhinitis, (rhino-)pharyngitis, tonsillitis, sinusitis, acute otitis media, laryngitis, (laryngo-)tracheitis, bronchitis, bronchiolitis, and (broncho)pneumonia, but excluding influenza-like illnesses (ILI).
Influenza-like illness (ILI)
ILI can be caused by a variety of microbial agents other than flu viruses. ILI is defined as an acute respiratory infection with sudden onset of fever, respiratory and general symptoms, such as general malaise or muscle pain.
Flu
Flu, or influenza, is a contagious infectious disease caused by the influenza virus (influenzavirus). The disease is characterized by the development of a flu-like syndrome. This refers to a combination of symptoms commonly associated with the illness, including: fever, chills, malaise, dry cough, loss of appetite, muscle aches and nausea.
COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that causes COVID-19. Symptoms of COVID-19 can vary widely, ranging from mild to severe, and may include fever, cough, difficulty breathing, loss of taste or smell, and fatigue. While many individuals recover without needing specialized treatment, COVID-19 can lead to serious complications, particularly in vulnerable populations.
Respiratory Synctitial Virus (RSV)
Symptoms usually appear 4 to 6 days after exposure (range: 2 to 8 days). RSV infection most often causes upper respiratory tract symptoms, which, in severe cases, may progress to lower respiratory tract illness. In infants, RSV is the leading cause of bronchiolitis and one of the main causes of hospitalization.
Severe Acute Respiratory Infection (SARI)
SARI is defined as a severe form of acute respiratory infection requiring hospitalisation for at least 24 hours. The case definition includes the presence of at least two acute respiratory symptoms (fever ≥ 38°C or history of fever, cough, respiratory distress such as dyspnoea, or abnormal lung auscultation). In children under 5 years of age, apnoea or cyanosis are also considered qualifying symptoms.
Severe complications
Among SARI patients, severe complications included death, acute respiratory distress syndrome (ARDS), admission to intensive care units (ICU), use of extracorporeal membrane oxygenation (ECMO), or invasive mechanical ventilation.
The following page presents information from surveillance, data collection, and analysis conducted by FARES/Respiratoire Gezondheid – BELTA. We invite you to consult the results in their reports using the links below:
Belgium is a low-incidence country for tuberculosis, with the number of new cases increasing in 2024 compared with 2023, reaching 8.1 per 100,000 inhabitants.
There were important regional differences, with the Brussels Capital Region having the highest number of new cases (22.4 new tuberculosis cases per 100,000 inhabitants).
The number of new cases of tuberculosis was higher in men, regardless of age, region or nationality.
More cases were reported in big cities, with Brussels reporting the highest number of new cases.
In Belgium, 47% of the tuberculosis notifications were in people of Belgian nationality.
2.Tuberculosis
Belgium is a low-incidence country with 8.1 cases per 100,000 inhabitants in 2024
In 2024, 950 new cases of tuberculosis were reported in Belgium (8.1 cases/100,000 inhabitants). Men were approximately 2 times more often affected by the disease than women, with 68% of new cases occurring among men in 2024 in Belgium. Of all cases, 41% of the tuberculosis patients diagnosed in 2024 were aged 25-44 years.
Among the regions of Belgium, the Brussels Capital Region has the highest number of new cases of tuberculosis
Of the total number of new registered cases, 47% of tuberculosis cases were registered in the Flemish Region (n=450), 30% in the Brussels Capital Region (n=280) and 23% in the Walloon Region (n=250). Considering the number of inhabitants in each region, the number of new cases was three times higher in the Brussels Capital Region (22.4 cases/100,000) as compared to the Flemish Region (6.6 cases/100,000) and the Walloon Region (6.0 cases/100,000) The number of new cases in the Flemish Region and the Walloon Region were similar, with slightly higher rates in the Flemish Region.
Tuberculosis occurs more often among people with non-Belgian nationality
In 2024, 63% of the new tuberculosis cases occurred among people of non-Belgian nationality. This proportion was higher in the Brussels Capital Region (70%) compared to the Walloon Region and the Flemish Region (respectively 56% and 62%).
Among people of Belgian nationality, the number of new cases was 3.8 times higher in the Brussels Capital Region (10.6/100,000) compared to the Flemish Region (2.8/100,000), and 1.1 times higher in the Walloon Region (3.0/100,000) than in the Flemish Region.
Among people of non-Belgian nationality, the number of new cases was 1.3 times higher in the Brussels Capital Region (42.4/100,000) compared to the Walloon Region (30.1/100,000), while it was 1.2 times higher in the Flemish Region (38.1/100,000) than in the Walloon Region.
The distribution of new cases of tuberculosis by age and sex varied according to nationality in 2024. The number of new cases was higher in men than in women across all age categories, except for children (0-14 years). The overall male-female ratio tended to increase with age, with a number of new cases being 2.0 times higher in men among those aged 30-44.
Among people of non-Belgian nationality, the highest number of new cases was observed in the 15-29 years age group, with particularly high numbers in men. The lowest number of new cases among people with non-Belgian nationality were seen in children (0-14 years). Excluding children (0-14 years), the number of new cases was 1.1 to 3.2 times higher in men compared to women across all age groups, with the highest male-to-female ratios in the 15-29 years and 45-59 years age groups.
Cases of tuberculosis are more often reported in the bigger cities
In 2024, tuberculosis occurred more frequently in big cities where more people at risk are living:
The number of new cases in the city of Brussels was the highest (22.4 new cases/100,000); it was 3 times higher compared to the overall number of new cases in Belgium (8.1 new cases/100,000).
The number of new cases was similarly high in Antwerp (21.7 new cases/100,000), followed by Liège (20.4 new cases/100,000), Charleroi (13.2 new cases/100,000), and Louvain (12.5 new cases/100,000).
Bruges was the only city where the number of new cases of tuberculosis was slightly lower than the national average (5.8 new cases/100,000).
In 2024, the number of new cases of tuberculosis remained low
The number of new cases of tuberculosis is decreasing for more than 40 years, although the diminution is slowing down since the nineties and tends to stagnate over the last few years. The number of new cases dropped below the level of 10 cases/100,000 for the first time in 2007, ranking the country among low-incidence countries. In 2024, the number of new cases (8.1 cases/100,000; n=950) remained low but was slightly higher compared to those after 2020, where the number of new cases (7.2/100,000) was the lowest number of new cases ever observed in Belgium, probably due to the context of the COVID-19 pandemic (including difficulty accessing healthcare, more complex data collection, under-reporting, containment measures, barrier measures, provision of emergency housing for vulnerable populations, border closures, etc.,).
Since 1981, the incidence rate is decreasing in all three regions, with more variations in Brussels:
In the Flemish Region, the number of new cases increased in 2024 (450 versus 320 in 2023). The number of new cases therefore rose to 6.6/100,000 versus 5.2/100,000 in 2023.
In the Brussels Capital Region, the number of new cases slightly increased from 21.3 cases/100,000 in 2023 to 22.4 cases/100,000 in 2024.
In the Walloon Region, it (6.0/100,000) is lower than in 2023 (6.9/100,000), and remains lower than the post-pandemic rebound observed in 2021 (7.2/100,000).
Despite being a low incidence country, Belgium ranks third in terms of number of new cases among EU-14 countries
In 2024, according to World Health Organization (WHO) [4], the estimated number of new cases in Belgium was above the EU-14 average, ranking the country 3rd in the EU-14 after Portugal and Spain.
International comparisons made on reported data must be interpreted with caution, since methods for collecting data are different depending on the country. That is why the WHO Global Task Force on TB Impact Measurement [1] has developed a methodology to take into account under reporting, over and under-diagnosis in tuberculosis estimates. It is than applied to all countries, while it might not be as relevant for every member state. This explains why the number of new cases in Belgium presented in this international comparison (8.0 new cases per 100,000) is different compared to the number of new cases extracted from the Belgian tuberculosis registry publication (8.1 cases per 100,000).
Number of new cases of tuberculosis per 100,000, EU-14 countries, 2024 Source: WHO/ECDC [4]
Tuberculosis is a disease caused by a bacterium called Mycobacterium tuberculosis that usually affects the lungs.
According to the World Health Organization (WHO), more than 10 million new cases of tuberculosis occur every year. Tuberculosis remains the world's deadliest infectious disease, causing more deaths annually than HIV or malaria.The disease is one of the top 10 causes of death worldwide, and probably returned to being the world’s leading cause of death from a single infectious agent in 2023, Belgium is situated among the “low-incidence countries” with less than 10 new cases of tuberculosis per 100,000 inhabitants per year [1].
Tuberculosis can nowadays be effectively treated and the success rate is 81% in 2023 in Belgium. In Belgium, treatment is free of charge for the entire population, also for people without health insurance. This through the BELTA-TBnet financing mechanism run by Respiratoire Gezondheid and FARES, with support by the RIZIV-INAMI. However, 7.3% of tuberculosis patients still die before the end of treatment [2].
The main risk factors for tuberculosis are contact with infected people, poverty, poor nutritional status and immunodeficiency. Some people are more likely to get infected with tuberculosis since they are more exposed to the disease, like health care professionals and vulnerable populations such as homeless people, prisoners, people living in reception centres and people originating from countries with high number of tuberculosis cases.
Data in this chapter are derived from surveillance activities, data collection, and analysis performed by Fonds des Affections Respiratoires (FARES) / Respiratoire Gezondheid – Belgian Lung and Tuberculosis Association (BELTA) [2,3]. Respiratoire Gezondheid [3] was previously known as the Vlaamse Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding (VRGT).
The number of new cases of tuberculosis is calculated as the number of new cases per 100.000 people registered at the National registry. The number of new cases among people with non-Belgian nationality is slightly overestimated, as cases in unregistered migrants are counted in the numerator, while the denominator could only include the registered migrants.
Definitions
EU-14
We compare the Belgian health status to the EU-14 because these countries have similar socioeconomic conditions. The EU-14 corresponds to all countries that belonged to the European Union between 1995 and 2004: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, and Sweden. Note: The United Kingdom is omitted since they have left the EU.
Tuberculosis case
According to the WHO-recommended definitions [5], a tuberculosis case is defined as a case of active tuberculosis clinically diagnosed by a clinician or other medical practitioner or bacteriologically confirmed. Clinically diagnosed cases include “cases diagnosed on the basis of X-ray abnormalities or suggestive histology and extrapulmonary cases without laboratory confirmation” [5].
WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2026 – 2024 data. Copenhagen: WHO Regional Office for Europe; and Stockholm:European Centre for Disease Prevention and Control; 2024. https://www.who.int/europe/publications/i/item/9789289062879
For a full picture of antimicrobial use and resistance in Belgium, explore the BELMAP platform. It brings together national data from humans, animals, food and the environment, with expert analysis, monitoring program links, and recommendations to strengthen surveillance. You can also access the full report for more in-depth information.
Antimicrobials are medicines used to kill or stop the growth of microorganisms that cause infections. They include antibiotics (against bacteria), antivirals, antifungals, and antiparasitics.
Antimicrobial resistance (AMR) occurs when microorganisms become resistant to these medicines, either naturally or through acquired resistance after repeated or inappropriate exposure (e.g. using antibiotics to treat viral infections).
This growing resistance is driven by:
Overuse and misuse of antimicrobials in humans and animals,
The spread of resistant strains between people, animals, and the environment.
A lack of new treatment options exacerbates the impact of growing resistance with serious consequences: ineffective treatments, longer infections, longer hospital stays, higher medical costs, and increased mortality. Fighting AMR is a global priority. It requires responsible use of antimicrobials, effective infection prevention, and continued investment in research and innovation.
Belgium tackles AMR through a One Health approach, recognising the link between human, animal, and environmental health. Key players include:
Sciensano: national surveillance, research, and guidance,
AMCRA and the Belgian Antibiotic Policy Coordination Committee (BAPCOC): veterinary antimicrobial use and awareness,
And collaboration with European partners such as the European Medicines Agency (EMA), European Centre for Disease Prevention and Control (ECDC), and European Food Safety Authority (EFSA).
Definitions
One Health
One Health stands for the pursuit of an holistic approach (which considers the whole and not at the sum of the different parts from which something is constructed) to health research in humans, animals, their environment and/or society by studying the interactions between these elements and their effect on health.
Vaccines are one of the greatest successes in global health, having safely reduced the morbidity and mortality of different infectious diseases and saved at least 154 million lives worldwide over the past 50 years.
In Belgium, as a result of vaccination, severe diseases like diphtheria or tetanus have become rare or even disappeared entirely (poliomyelitis, smallpox, congenital rubella).
Even though circulation of most diseases has decreased, high vaccination coverage remains necessary and outbreaks can still occur due to immunity gaps in the population.
Vaccination coverage for infants is high (>90%) throughout Belgium for all vaccines included in the free basic vaccination programs and is comparable between regions.
Coverage declines after childhood: it is lower among adolescents, and even lower among adults in risk groups, with substantial regional disparities.
2.Epidemiology of some vaccine-preventable diseases
Success stories: no more polio and rubella in Belgium
Poliomyelitis is a highly infectious viral disease. It causes mild or no symptoms in most people, but in some people it can cause total paralysis or death. After the introduction of the polio vaccination in 1956, the incidence of polio sharply declined and cases have been rare following the introduction of mandatory vaccination in 1967. Since 2002, the European region has been considered polio-free by the World Health Organization (WHO). Currently, the risk of an epidemic in Belgium is low thanks to the high vaccination coverage.
Similarly, Belgium was certified by WHO as having eliminated rubella, thanks to vaccination. This virus can have severe consequences during pregnancy leading to stillbirth, congenital malformations and congenital rubella syndrome (CRS). The last autochthonous case of CRS in Belgium dates from 2007 and the last imported case from 2012. However, as long as these viruses are still circulating elsewhere, vaccination and surveillance remain necessary due to the risk of importation.
Disease outbreaks still occur due to immunisation gaps in the population
For most diseases targeted by vaccination, incidence has dropped drastically since the start of routine vaccination, but outbreaks still occur. Under-immunisation of certain groups or geographical regions significantly increases the risk of outbreaks. There was, for example, a diphtheria outbreak among asylum seekers in 2022, a group where vaccination remains difficult and coverage is too low [2].
In 2024, an important measles outbreak occurred, affecting mostly unvaccinated schoolchildren in Brussels. Also in 2025, case numbers remained elevated, this time mostly in Flanders due to an outbreak in a largely unvaccinated community in Antwerp. Both examples highlight the importance of high vaccination coverage throughout the entire population.
Shifts in circulating serotypes of invasive infections slow down the success of vaccination campaigns
For invasive diseases like meningococcal and pneumococcal disease, current vaccines protect against certain serogroups/serotypes, but not all. Since the introduction of these vaccines in Belgium, circulation of strains included in the vaccine has dropped significantly. However, other strains not covered by the vaccine in the schedule are on the rise. This changing epidemiology does not indicate a failure of the vaccination policy, as total incidence remains lower than before vaccination programs were introduced. It does however highlight the need for development of new vaccines and adjustments in vaccination schedules. For example, the meningococcal vaccine was changed from MenC to MenACWY in 2023 to include three additional serogroups, after an increase in serogroups W and Y was observed. Also for pneumococcal disease, since 2025 the Superior Health Council recommends switching from PCV13 (which protects against 13 types of pneumococci) to PCV20 (which protects against 20 serotypes). This change would protect against 7 additional serotypes that are on the rise in Belgium, together responsible for half of all IPD cases in young children. Implementation of this recommendation is currently under consideration. For now PCV13 remains the vaccine provided in the free vaccination program.
3.1. Vaccination coverage for children under 2 years old
Vaccination coverage in Belgium is high and stable over time
In Belgium, the 90% coverage threshold set out in the WHO's Global Vaccine Action Plan (GVAP) [3] has been reached for full primary vaccination (1-4 doses depending on the vaccine) for all vaccines included in the recommended basic vaccination schedule, except for the rotavirus vaccine. The rotavirus vaccine is the only vaccine that is recommended for children but not provided in the free-of-charge vaccination program.
Vaccination coverage for vaccines in the basic vaccination programs is comparable for all Belgian regions
Vaccination coverage for vaccines in the basic vaccination programs for children is consistently high across all Belgian regions. National vaccination coverage for the full schedule (4 doses) of the hexavalent vaccine is 94%, with comparable coverage rates in all regions. The hexavalent vaccine is a vaccine that combines vaccination against six diseases in 1 shot (diphtheria-tetanus-pertussis (DTP), hepatitis B (HebB), Haemophilus Influenza type b (Hib), and poliomyelitis (polio)). Similarly, coverage for meningococcal (92%) and pneumococcal (94%) vaccines, as well as the first dose of measles-mumps-rubella (MMR1), show minimal regional differences.
Rotavirus coverage is lower in Brussels and Wallonia
The rotavirus vaccine is recommended by the Superior Health Council (SHC) but is not included in the free vaccination programs by the regions. It is partially reimbursed by the RIZIV-INAMI, but parents still have to pay €7-12 per dose out of pocket. As a result, vaccination rates were lower than for the free vaccines in the basic vaccination program, especially in Brussels (69%) and Wallonia (80%). In Flanders, on the other hand, vaccination coverage was 92%. Recent analyses have further highlighted persistent inequalities in rotavirus vaccine uptake in Belgium, with lower vaccine uptake in socioeconomic vulnerable families and certain geographical areas. [9]
3.2. Vaccination coverage for adolescents
WHO targets for MMR and HPV vaccination coverage are not being met
The WHO targets of 95% for 2 documented doses of mumps, measles and rubella (MMR2) and ≥ 90% for human papillomavirus (HPV) coverage have not been reached in Belgium. Based on the latest available surveys, the weighted national average coverage for MMR2 has decreased from 82% to 73%, although it is unclear whether this represents a true decrease or rather an artefact due to limitations in the data*.
The national coverage for full HPV vaccination (2 doses) is 72% for girls, 65% for boys and 68% for girls and boys together. HPV vaccination has slowly been increasing over the years for girls. In 2019, vaccination for boys was introduced. Coverage in boys is currently lagging behind that of girls.
*Interpretation note The reported MMR2 coverage should be interpreted as a lower limit. The apparent decrease may be explained by findings from the 2024–2025 vaccination coverage survey in the French-speaking community. Following the lowering of the recommended age for the second MMR dose from 11–12 years to 7–8 years, a smaller proportion of vaccinations were delivered through school health services, while more parents (18%) reported intending to vaccinate their child through their general practitioner. As current vaccination registries cannot verify the vaccination status of these children, they are not included in the reported number of vaccinated adolescents.
Important regional differences in coverage rates for adolescents
For adolescent vaccination, there are regional differences in both schedule and vaccination uptake. Following the advice from the Superior Health Council to lower the age for the second dose of MMR2, the French Community (FWB) and German-speaking Community lowered the age to 7-8 years old and the Flemish Community to 9-10 years old. In October 2025, Flanders lowered the age for MMR2 even further, to 24 months. In Flanders, the latest survey was performed in 2020, reporting coverage of 89%. FWB performed a new coverage survey in 2024-2025 that indicated a 52% coverage in the whole French Community and 59% for Brussels specifically*.
Also for HPV, the weighted national average hides important regional differences. In 2019-2020, Flanders had a full HPV vaccination coverage rate of 81% for both girls and boys, while the French Community had a coverage of 48%. In a new survey by FWB in 2022-2023, coverage in the French Community increased to 52%. Coverage in Brussels specifically increased from 39% to 41%.
Vaccination is a lifelong intervention. While vaccination programs for infants and adolescents are well established, vaccination of adults remains more fragmented in Belgium. Consequently, vaccination coverage data are limited, but available evidence indicates that uptake of recommended vaccines among older adults, pregnant women and other risk groups remains suboptimal. For example, 51% of adults in risk groups eligible for influenza vaccination received an influenza vaccine in 2023, and only 14% of adults in risk groups had been vaccinated against pneumococcal disease [12]. Regional differences, already observed in adolescents, become even more pronounced in adulthood. For example, maternal pertussis vaccination coverage reached 85% in Flanders, compared with 39% in Wallonia and 31% in Brussels [4].
The Belgian Superior Health Council decides, on a scientific basis, about the recommended vaccination schedule for children. This schedule currently includes vaccines for thirteen infectious diseases. Of these, the polio vaccine is the only one that is mandatory in Belgium. The different communities (Flemish, French and German-speaking Community) are then responsible for the implementation of the guidelines and practical organization of the vaccination campaigns. As a result, there are some regional differences in the age of administration of certain vaccines for children (see schedules for Flanders and Fédération Wallonie-Bruxelles) and in the vaccine brands that are being used. Extensive information can be found in the report “Vaccination policy and advice in Belgium” (available in Dutch and French).
In Belgium, vaccination coverage is monitored by coverage surveys organized and financed by the relevant regions/communities. These surveys take place approximately every four to five years. An estimate of national vaccination coverage in Belgium is calculated each year by Sciensano's Epidemiology of Infectious Diseases Department on the basis of the most recent vaccine coverage studies and weighted by population size. To study infant vaccination coverage, the same methodology is used in all three regions, with a sample drawn from the general population. The method used to study adolescent vaccination coverage differs from region to region. In Flanders, adolescent vaccination coverage studies are carried out on a general population sample. In Brussels and Wallonia, vaccination coverage surveys have been carried out every year on a sample of pupils in French-speaking schools [4]. In Flanders, an electronic vaccination registry, Vaccinet, has existed since 2006 and is being routinely used by all vaccinators. For the French community, new vaccination registries are currently being rolled out. In the future, registry-based vaccination coverage estimates might replace the periodical surveys.
Epidemiological reports
More detailed information on the epidemiology and surveillance of vaccine-preventable diseases can be found in the yearly reports on the specific health topic pages on Sciensano website:
Localized communities with low vaccine uptake (e.g., specific demographic groups, geographical areas, hard-to-reach communities, etc.), increasing their susceptibility to infection and the likelihood of outbreaks.
Serotypes/serogroups
Describes a way of grouping cells or microorganisms, such as bacteria, based on the antigens or other molecules found on their surfaces.
Vaccine coverage
Percentage of persons who received certain vaccine doses. For example, coverage of DTP3 is the percentage of infants who received all three doses of diphtheria, tetanus and pertussis (DTP) vaccine.
Primary vaccination
The initial series of vaccinations given to an individual to achieve immunity against a particular disease, usually involving multiple doses administered (1-4 depending on the vaccine) over a specified period to build a strong and long-lasting immune response.
Jacquinet S, Martini H, Mangion J, Neusy S, Detollenaere A, Hammami N. Outbreak of Corynebacterium diphtheriae among asylum seekers in Belgium in 2022: operational challenges and lessons learnt. Eurosurveillance. 2023. https://doi.org/10.2807/1560-7917.ES.2023.28.44.2300130
World Health Organization. Global vaccine action plan: monitoring, evaluation and accountability: secretariat annual report 2020. https://iris.who.int/handle/10665/337433
Dambre C, Rousseau R, Hansford K, Cornelissen L. Analyse du taux de vaccination et des déterminants socio-économiques sur la base des données de remboursement de l’AIM. 2026. https://hdl.handle.net/20.500.14493/5861
Brasseur C, Sarr K. Résumé enquête de couverture vaccinale 2022-2023. La vaccination contre le papillomavirus humain (HPV) chez les élèves de 2ème secondaire dans l’enseignement de la Fédération Wallonie-Bruxelles. https://www.ccref.org/e-vax/pdf/ECV_2022-2023_HPV_Resume.pdf
In 2024, 662 people were newly diagnosed with HIV in Belgium, with the total number remaining stable compared to 2023.
An increase was observed among Belgian men, both heterosexual and men who have sex with men (MSM).
289 MSM were newly diagnosed, the same as in 2023, but diagnoses among Belgian MSM rose by 15%.
332 heterosexual people were newly diagnosed (175 women and 157 men), a 3% increase from 2023. Among women, diagnoses remained stable for Belgian women but decreased for women of other nationalities. Among men, diagnoses increased, with a 33% rise specifically among Belgian heterosexual men.
Overall, the epidemic mainly affects Belgian MSM and heterosexual men and women from sub-Saharan Africa.
Brussels remains disproportionately affected, with a diagnosis rate almost three times higher than the national average.
2.New diagnoses of HIV infections in 2024
In 2024, 662 new diagnoses of HIV infections were made in Belgium (5.6 new diagnoses per 100.000 inhabitants, or on average 1.8 cases a day). Among those, 71% were men. 75% of the HIV infections were diagnosed in people aged 20-49.
New HIV diagnoses have increased for 4 consecutive years (2021-2024)
The number of new HIV diagnoses in 2024 is similar to that of 2023 (+2%). An increase in the number of new HIV diagnoses has been observed over the last four years, following a steady decline in the years preceding the COVID-19 pandemic.
Between the start of the epidemic in the early 80s and the end of 2024, a total of 32,401 persons were diagnosed with HIV, and a total of 5,742 cases of AIDS were reported.
Brussels has a higher diagnosis rate compared to the rest of Belgium
In 2024, of the 662 newly diagnosed persons, 201 were resident in the Brussels-Capital Region, 273 in the Flemish Region, 179 in the Walloon Region, and 9 were residing abroad.
When accounting for the number of inhabitants, the incidence rates in the Flemish Region (max 7 for 100,000 inhabitants in Ostende district) and in the Walloon Region (max 8/100,000 in Arlon; 7/100,000 in Tournai-Mouscron and Bergen districts) are comparable, while the rate in the Brussels Capital Region is still much higher (16/100,000).This difference is not surprising since a higher HIV prevalence is a common phenomenon in a big city. The Brussels Capital Region can indeed be considered a big city - with the socio-cultural characteristics of an urban context – while the two other regions mix rural, semi-urban, and urban contexts. In addition, Brussels has specific characteristics as a capital city, with high international population mobility and an overrepresentation of certain population groups at higher risk.
Continued increase in new diagnoses observed in the Walloon Region from 2021 to 2024
Following a decline over the previous decade, an increase in newly diagnosed people in the last three years was observed at national level in all three regions. This increased continued only in the Walloon Region in 2024.
Diversification in the 2-key populations in Belgium
The HIV epidemic in Belgium mainly affects two populations: men who have sex with men (MSM), mostly of Belgian nationality, and men and women who have contracted the virus through heterosexual intercourse, mainly from sub-Saharan Africa.
However, among both MSM and heterosexuals, the distribution of nationalities changes significantly over time. In 2024, 289 new HIV diagnoses were made among MSM, the same number as 2023. Among them, diagnoses among MSM of Belgian nationality increased by 15% compared with 2023; representing 56% of HIV diagnoses among MSM in 2024. In addition, 15% of MSM diagnosed had another European nationality and 14% had a Latin American nationality.
In 2024, 332 HIV diagnoses were reported among heterosexual people, a number similar to 2023 (+3%). Among women (175), there was a slight decrease (–5%), while an increase was observed among men (157; +13%). The number of diagnoses remained stable among Belgian women but decreased among women of other nationalities. Among men, the overall increase was mainly driven by Belgian men (+33%) and, to a lesser extent, by men of other nationalities.
Close to 20,000 persons were living with HIV in Belgium in 2024
By the end of 2024, an estimated 19,183 individuals were living with HIV in Belgium. Among them, 94% had received a diagnosis, and of those diagnosed, 95% were undergoing antiretroviral treatment, and of those on treatment, 98% had reached viral suppression, accounting for 88% of all people living with HIV.
More than a thousand people in Belgium live with an undiagnosed HIV infection
In 2024, Sciensano estimated the number of people living with undiagnosed HIV[1] based on a tool developed by ECDC [2]. It is estimated that 1224 people living with HIV in Belgium were unaware of their HIV status. However, these estimates should be interpreted with caution given the significant uncertainty surrounding the estimates for the last 3 years derived from this model. Based on the ECDC tool, the number of people living with undiagnosed HIV in Belgium appears to have been steadily declining since 2011.
Sexually transmitted infections (STIs) such as human immunodeficiency virus (HIV) are spread primarily through person-to-person sexual contact. Additionally, HIV can be transmitted through blood products – such as drug injection - and tissue transfer, and perinatally during pregnancy or breastfeeding.
HIV can be present without symptoms, which can facilitate transmission. It is one of the most serious communicable diseases in Europe. Infection with the virus can, if antiretroviral treatment (ART) is not initiated, lead to serious morbidity (Acquired Immunodeficiency Syndrome (AIDS)) and requires life-long treatment.
HIV is an avoidable infection since the transmission is largely preventable by behavioural measures (safe sex, safe injection). Therefore HIV incidence in a defined population is an indicator of the success/failure of control strategies. Since 2017, the use of pre-exposure prophylaxis to HIV (PrEP) is reimbursed in Belgium.
Surveillance of HIV in Belgium
The epidemiological surveillance of HIV in Belgium dates from 1985 and is carried out by Sciensano on the basis of the registration of new HIV diagnoses. These data are reported by the seven AIDS reference laboratories that perform all confirmations of positive HIV screening tests. In addition to recording the number of newly diagnosed HIV positive persons, the laboratories also collect basic epidemiological data on sex, age, nationality, probable route of infection, and clinical stage at the time of diagnosis. Sciensano also collects data on the people living with HIV (PLWH) in care in Belgium (HIV cohort data) from the AIDS reference laboratories and the HIV reference centres.
Besides the newly diagnosed cases, Sciensano also estimates the number of people living with HIV: those who have not yet been diagnosed [1] and those living with a diagnosed infection. To estimate the undiagnosed population an instrument developed by the European Center for Disease Prevention and Control (ECDC), called the ECDC HIV Modeling Tool [2] is used. HIV cohort data are used to estimate the number of people living with a diagnosed infection.
ECDC and the WHO Regional Office for Europe jointly coordinate HIV/AIDS surveillance in Europe [3]. The international comparability has some limitations since the national surveillance systems differ in levels of underreporting and reporting delay.
Definitions
New HIV diagnoses
A new HIV diagnosis is defined as a first HIV diagnosis. People, mainly foreigners, with an HIV diagnosis or in care for HIV in another country before their diagnosis was confirmed in Belgium are treated separately. People with known HIV infection do not represent a population that could have benefited from prevention measures in Belgium and are therefore presented separately. More information on them can be found in the annual epidemiological report.
HIV/AIDS
HIV infection and AIDS are the acronyms of "Human Immunodeficiency Virus" (HIV) infection and "Acquired Immune Deficiency Syndrome" (AIDS). Initial HIV infection is most often asymptomatic, while people may experience influenza-like symptoms. This is followed by a prolonged period with no symptoms. If the infection progresses, it interferes more with the immune system, increasing the risk of developing infections such as tuberculosis, as well as other opportunistic infections, and tumours which are rare in people who have a normal immune function. These late symptoms of infection are referred to as AIDS. Since the late 1990s, efficient antiretroviral treatment exists that can control the progression of the disease.